Lansing Street Advisors Trims Stock Position in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Lansing Street Advisors decreased its position in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 20.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,764 shares of the company’s stock after selling 2,306 shares during the period. Lansing Street Advisors owned 0.13% of VanEck Pharmaceutical ETF worth $802,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Private Advisory Group LLC lifted its stake in shares of VanEck Pharmaceutical ETF by 0.3% during the 2nd quarter. Private Advisory Group LLC now owns 37,994 shares of the company’s stock worth $3,476,000 after purchasing an additional 128 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of VanEck Pharmaceutical ETF by 2.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,296 shares of the company’s stock valued at $594,000 after purchasing an additional 185 shares during the period. Optimum Investment Advisors acquired a new position in shares of VanEck Pharmaceutical ETF in the second quarter valued at about $27,000. Aspiriant LLC raised its stake in shares of VanEck Pharmaceutical ETF by 5.6% in the first quarter. Aspiriant LLC now owns 6,000 shares of the company’s stock worth $544,000 after purchasing an additional 320 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in VanEck Pharmaceutical ETF by 2,343.8% in the first quarter. Global Retirement Partners LLC now owns 391 shares of the company’s stock valued at $35,000 after buying an additional 375 shares during the last quarter.

VanEck Pharmaceutical ETF Trading Up 0.1 %

PPH opened at $97.10 on Thursday. The firm has a 50 day moving average of $94.82 and a two-hundred day moving average of $91.39. The firm has a market capitalization of $654.45 million, a PE ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a 12-month low of $74.05 and a 12-month high of $99.51.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, July 5th. Investors of record on Monday, July 1st were given a dividend of $0.3558 per share. The ex-dividend date of this dividend was Monday, July 1st.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.